JAMES GRAMLING: Open Payments
NPI 1366842015 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,763 in 97 payments from 17 companies in 2025. Trend: 2023 $1,057 · 2024 $2,038 · 2025 $1,763
Food & beverage: $1,763
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 13 | $275 |
| AstraZeneca Pharmaceuticals LP | 12 | $243 |
| PFIZER INC. | 12 | $208 |
| Novo Nordisk Inc | 9 | $160 |
| ABBVIE INC. | 11 | $151 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $151 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $113 |
| Amgen Inc. | 5 | $91 |
| Astellas Pharma US Inc | 3 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
Products named: GEMTESA, Kerendia, BREZTRI, NURTEC ODT, XIFAXAN, FARXIGA, REXULTI, Veozah.
Industry payments across AL — which companies pay providers there.
